HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Cardiac Amyloidosis: An Overlooked but Treatable Cause of HFpEF

Inova Heart and Vascular Institute - Advanced Heart Failure Symposium

SOHO 2022: Amyloidosis - Update and How To Use Novel Agents

SOHO 2022 Tenth Annual Meeting

S. Lentzsch

Amyloidosis Types and Pathophysiology

Houston Methodist

B. Trachtenberg

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

Emerging Therapies in Cardiac Amyloidosis

NYU Langone

M. Hanna

New Diagnostic and Treatment Strategies in Cardiac Amyloidosis

Canadian Collaborative Research Network

M. Davis

Therapies for Pulmonary Venous Hypertension: Updates on the Treatmen…

Scripps Health

R. Mohan

Cardiac Amyloidosis: Evaluation and New Therapies

Cleveland Clinic Heart, Vascular and Thoracic Institute

M. Hanna

Overview of Cardiac Amyloidosis

Yale Cancer Center

E. Miller

Lessons from the 2023 ACC Expert Consensus Decision Pathway on Compr…

Michelle Kittleson

Clinical Presentation of Amyloidosis: Who to Suspect? - a 2022 Update

Scripps Health

R. Mohan

Cardiac Amyloidosis: Who to Suspect?

Scripps Health

R. Mohan

AHA 2022: Genomic Therapies for Hereditary Transthyretin (TTR) Amylo…

AHA 2022 Conference Coverage

M. Fontana

Cardiac Amyloidosis vs. Cardiorenal Syndrome: How to Diagnose and Tr…

16th Annual Heart Failure Holiday Symposium

M. Grogan

Updates on Cardiac Amyloidosis: A “Rare” Disease Hiding in Plain Sig…

Courage and Innovation Symposium: Heart Failure & Heart Transplantation

N. Sarswat

Treatment Options for AL Amyloidosis

Houston Methodist

A. Dispenzieri

Cardiac Amyloidosis: It's Right in Front of You

Norman Lepor

Renal Amyloidosis

Houston Methodist

J. Gonzalez

Updates on the Diagnosis and Management of Amyloidosis

Penn Medicine Heart and Vascular Center

B. Drachman